Dr. Reddy's Laboratories launches Febuxostat Tablets in U.S. market

Dr. Reddy's Laboratories announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health.

Dr. Reddy's Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets

Powered by Capital Market - Live News